Skip to main content
← All trials
Relapsed or Refractory Multiple Myeloma (RRMM)GeneticsCancerDrugPhase 3

What this study is

The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.

What's being tested

  • BMS-986393

    Intervention · DRUG

  • Cyclophosphamide

    Intervention · DRUG

  • Fludarabine

    Intervention · DRUG

  • Daratumumab

    Intervention · DRUG

  • Pomalidomide

    Intervention · DRUG

  • Dexamethasone

    Intervention · DRUG

  • Carfilzomib

    Intervention · DRUG

All interventions

Specified dose on specified days

Study details

Official title
A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma
Sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Conditions
Relapsed or Refractory Multiple Myeloma (RRMM)
Enrolling
440 people
Starts
2025-03-12
Est. completion
2032-06-22
Design
Open-label, randomized, parallel groups, Phase 3
Record
View on ClinicalTrials.gov ↗